Treating Prostate Cancer

Dendreon Corp (DNDN) is a biopharma co. developing immunotherapeutic meds for cancer patients. More on their Provenge drug and how it works which is interesting here

From the chart perspective, DNDN is forming a 6 months Head & Shoulders bottom with 3.60 as the neckline. Will selling Provenge in Europe act as the reversal ? Implied target is $5

Do note the gap above which usually serves as resistance.


STOP searching for trades & subscribe or follow me @theartofchart


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s